Dexmedetomidine: Side Effects, Uses & Monitoring
1.1 Intensive Care Unit Sedation Dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting.
- Data source
- FDA labeling via NIH DailyMed (label 42cbeadf…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Hypotension requiring intervention | 28% |
| Hypotension | 25% |
| Hypertension | 19% |
| Hypokalemia | 13% |
| Nausea | 11% |
| Tachycardia requiring intervention | 10% |
| Anxiety | 9% |
| Atrial fibrillation | 7% |
| Hypomagnesemia | 7% |
| Atelectasis | 6% |
| Pleural effusion | 6% |
| Constipation | 6% |
| Hypoglycemia | 6% |
| Generalized edema | 6% |
| Bradycardia | 5% |
| Vomiting | 5% |
| Hypovolemia | 5% |
| Ventricular tachycardia | 5% |
| Fever | 5% |
| Bradycardia requiring intervention | 5% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
1.1 Intensive Care Unit Sedation Dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine injection prior to extubation. 1.2 Procedural Sedation Dexmedetomidine injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Pediatric use information is approved for Hospira Inc.’s PRECEDEXTM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.
Frequently Asked Questions
What is Dexmedetomidine used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Dexmedetomidine?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Dexmedetomidine. Individual risk varies.
Does Dexmedetomidine require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Dexmedetomidine.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.